{
    "organizations": [],
    "uuid": "cb7ee3cfe2474ece0db9d2d4b0aa5350cdea7e50",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-redwood-pharma-asian-pharmaceutica/brief-redwood-pharma-asian-pharmaceutical-firm-to-evaluate-intelligel-idUSFWN1QG0T3",
    "ord_in_thread": 0,
    "title": "BRIEF-Redwood Pharma: Asian Pharmaceutical Firm To Evaluate IntelliGel",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 26 (Reuters) - REDWOOD PHARMA AB:\n* ASIAN PHARMACEUTICAL FIRM TO EVALUATE INTELLIGEL * ‍ASIAN PHARMACEUTICAL FIRM WILL OBTAIN INTELLIGEL FOR PURPOSES OF EVALUATING DRUG DELIVERY PLATFORM​\n* ‍AGREEMENT DOES NOT RESULT IN ANY PAYMENTS TO REDWOOD PHARMA​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-02-26T20:08:00.000+02:00",
    "crawled": "2018-02-27T15:05:04.014+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "redwood",
        "pharma",
        "ab",
        "asian",
        "pharmaceutical",
        "firm",
        "evaluate",
        "intelligel",
        "pharmaceutical",
        "firm",
        "obtain",
        "intelligel",
        "purpose",
        "evaluating",
        "drug",
        "delivery",
        "result",
        "payment",
        "redwood",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}